Meiji

Meiji, established in 2001, operates within the Manufacturing and Food, Beverages & Tobacco sectors, generating $7.2B in revenue. The company is primarily engaged in the confectionary and pharmaceutical industries. Its pharmaceutical division is dedicated to the discovery, development, and commercialization of a diverse range of pharmaceutical products, serving markets both within Japan and internationally. Meiji possesses significant expertise and capabilities, particularly in the development and commercialization of antibiotic products, with a strong focus on infectious diseases and central nervous system (CNS) disorders.

With an employee base exceeding 10,000 individuals and operations spanning 2 locations, Meiji maintains a robust operational framework. The company's commitment to innovation and product development is supported by its dedicated workforce, and you can Meet Meiji's team to learn more about their leadership and operational structure. This extensive team contributes to Meiji's capacity to address complex health challenges and deliver high-quality products across its business segments. The company's strategic focus on R&D ensures a pipeline of advanced solutions.

Meiji's market presence is characterized by its engagement in both business-to-business (B2B) and business-to-consumer (B2C) models, as indicated by its diverse hashtag profile. Geographically, the company has a notable presence in Asia, with specific operations in Singapore, contributing to its broader regional and global footprint. Further details on its business activities and market positioning can be explored via its corporate website, www.meiji.com.sg. The company's strategic initiatives aim to expand its reach and impact in its core industries.